SECISBP2L and B-cell chronic lymphocytic leukemia: Similarly, in the group of CLL patients, a significantly higher percentage of CD14dimCD16+SLAN+ non-classical monocytes (median; IQR), namely 8.19 (5.11–12.61%), was found as compared to that of the control group (median; IQR), 5.20 (3.10–9.27%) (p < 0.01) (Figure 2C).